Pregnancy outcomes in women with Ebstein’s anomaly
To evaluate whether women with Ebstein’s anomaly can tolerate pregnancy and whether the perinatal outcomes are influenced by the severity of Ebstein’s anomaly.
Data of four women with Ebstein’s anomaly delivered in our unit were collected and analyzed retrospectively.
(1) Two women with Ebstein’s anomaly had uneventful pregnancies, cesarean section and puerperium. (2) The patient with the most serious Ebstein’s anomaly (with central cyanosis and clubbing) had an episode of paroxysmal ventricular tachycardia and spontaneous cardioversion to sinus rhythm on day 4 postpartum. She developed intracerebral hemorrhage on day 25 postpartum. (3) One of them suffered from atrial flutter on 38 + 3 weeks of gestation which was restored to sinus rhythm after being treated with verapamil and remained stable afterward. (4) All neonatal birth weights were more than 2,500 g, and all neonatal Apgar scores were 10 at 1 min. (5) The gestational age at delivery of our cases was from week 36 + 4 to week 38 + 4. The mean duration of follow-up was 56 days postpartum.
(1) The clinical features of pregnant women with Ebstein’s anomaly vary. They might have good perinatal outcomes when given appropriate treatment. (2) Those with cyanosis should be given more attention, as they can have more complications during pregnancy, delivery and puerperium. (3) All women with Ebstein’s anomaly should be offered fetal echocardiography during pregnancy. (4) Vaginal delivery is advised for most cases with Ebstein’s anomaly.
KeywordsEbstein’s anomaly Pregnancy Perinatal outcomes Congenital heart disease
We acknowledge Feng Xu, M.D., for his helpful edits.
Conflict of interest
- 7.Choi YH, Park JH, Choe YH, Yoo SJ (1994) MR imaging of Ebstein’s anomaly of the tricuspid valve. Am J Roentgenol 163:539–543Google Scholar
- 14.Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, Scarselli GF, Gensini GF, Abbate R (2005) Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 45:86–91PubMedGoogle Scholar
- 18.Draisci G, Valente A, Suppa E, Frassanito L, Pinto R, Meo F, De Sole P, Bossù E, Zanfini BA (2008) Remifentanil for cesarean section under general anesthesia: effects on maternal stress hormone secretion and neonatal well-being: a randomized trial. Int J Obstet Anesth 17(2):130–136PubMedCrossRefGoogle Scholar
- 20.European Society of Gynecology; Association for European Paediatric Cardiology; German Society for Gender Medicine; Authors/Task Force Members, Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L; ESC Committee for Practice Guidelines, Bax J, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Baumgartner H, Deaton C, Aguiar C, Al-Attar N, Garcia AA, Antoniou A, Coman I, Elkayam U, Gomez-Sanchez MA, Gotcheva N, Hilfiker-Kleiner D, Kiss RG, Kitsiou A, Konings KT, Lip GY, Manolis A, Mebaaza A, Mintale I, Morice MC, Mulder BJ, Pasquet A, Price S, Priori SG, Salvador MJ, Shotan A, Silversides CK, Skouby SO, Stein JI, Tornos P, Vejlstrup N, Walker F, Warnes C (2011) ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 32(24):3147–3197Google Scholar
- 21.Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (2003) Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 24(8):761–781Google Scholar